Publication

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Authors not recorded

Cancer Discov2016PMID 27102076PMC4893907stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (9)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 9

cancerLung Adenocarcinomacivic_curation1.00
drugCetuximabcivic_curation1.00
drugErlotinibcivic_curation1.00
geneEGFRcivic_curation1.00
genePURBcivic_curation1.00
geneRAD51civic_curation1.00
variantEGFR L858Rcivic_curation1.00
variantPURB Fusioncivic_curation1.00
variantRAD51 Fusioncivic_curation1.00

Curated evidence

Evidence citing this paper (7)

civicCuratedShowing 1–7 of 7 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR L858R2
Cetuximab	Lung Adenocarcinoma	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID4292 In an in vitro study, Ba/F3 cell line expressing EGFR L858R did not show sensitivity to cetuximab treatment, while cells expressing EGFR-RAD51 fusion were sensitive. Sensitivity was determined by asse… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
Erlotinib	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID4291 In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to erlotinib treatment (IC50 26.9 ± 12.4nM). EGFR L858R was used as a positive control for comparing sensiti… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
PURB Fusion1
Erlotinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID10996 A metastatic lung adenocarcinoma (bone and brain) was diagnosed in a 42-year-old woman (patient 3). The primary adenocarcinoma was found in left lower lobe (LLL). Her initial treatment with whole-brai… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
RAD51 Fusion4
Afatinib	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID11019 Response to Afatinib was assessed by measuring viability of Ba/F3 cells expressing the EGFR::RAD51 variant 72 hours after treatment with Afatinib (10-1000 nmol/L). Viability was measured using the Cel… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
Erlotinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	4	accepted	EID11015 The paper reports three patients (P1, P2 and P4) with Stage IV lung adenocarcinoma with metastasis, harboring the EGFR::RAD51 fusion detected by hybrid capture NGS (FoundationOne). Breakpoints were in… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID11017 Response to Erlotinib was assessed by measuring viability of Ba/F3 cells expressing the EGFR::RAD51 variant 72 hours after treatment with Erlotinib (10-1000 nmol/L). Viabilty was measured using the Ce… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	4	submitted	EID11016 Expression of EGFR::RAD51 via retroviral transfection in IL-3 dependent murine Ba/F3 cells results in activation of Pi3K/AKT pathway (Fig. 2C, increased levels of pAKT), and IL-3 independent prolifera… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic